Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Tesaro's On The Right Path With Anti-PD-1 Dostarlimab In Endometrial Cancer

Mar 22 2019

• By Emily Hayes

Businessman going straight ahead on a red carpet arrow between two maze

Related Content

Merck KGAA/Pfizer Discontinue Phase III Avelumab/Talazoparib Combo Study In Ovarian Cancer

Mar 20 2019

AZ Lynparza Head Hopes 2020 Will See PARP Inhibitor Treating Pancreatic Cancer

Feb 26 2019

Clovis In Pole Position To Be First PARP For Prostate Cancer

Oct 22 2018

Sanofi/Regeneron's IO Springboard Libtayo Cleared For Skin Cancer

Sep 29 2018

Merck KGAA/Pfizer's Bavencio Failure Casts More Shade On Immunotherapy For Ovarian Cancer

Dec 24 2018

First-Line Ovarian Cancer Approval Solidifies Lead For AstraZeneca's Lynparza

Dec 19 2018

GSK Embraces PARP Promise With Tesaro Buy

Dec 03 2018

Ovarian Cancer Pipeline Review: Sponsors Plan Frontline Punch, Smart Combinations

Dec 07 2018

Ovarian Cancer Market Snapshot: AstraZeneca's Lynparza Poised To Lead In Niche Space

Dec 07 2018

Keytruda Approval Opens New Routes For Immuno-Oncology

May 25 2017

Related Companies

Tesaro, Inc.

GSK plc

Merck & Co., Inc.

Sanofi

Regeneron Pharmaceuticals, Inc.

AstraZeneca PLC

Clovis Oncology, Inc.

Pfizer Inc.

Merck KGaA

Additional Topics

Research & Development Cancer Gynecology & Urology BioPharmaceutical

More from R&D

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window